Pharmaceutical Research

, Volume 18, Issue 12, pp 1742–1746 | Cite as

Enhanced Bioavailability of Calcitonin Formulated with Alkylglycosides Following Nasal and Ocular Administration in Rats

  • Fakhrul Ahsan
  • John Arnold
  • Elias Meezan
  • Dennis J. Pillion


Purpose. The purpose of this study was to characterize the effects of alkylglycosides on the bioavailability of calcitonin following nasal and ocular administration.

Methods. A salmon calcitonin specific radioimmunoassay kit was used to measure calcitonin levels in anesthetized rats at various times after nasal or ocular administration of calcitonin formulated with saline or with octylmaltoside, a medium chain length alkylglycoside or tetradecylmaltoside, a long chain alkylglycoside. The extent of calcitonin absorption was determined directly from the plasma calcitonin level-time curve and the bioavailability of calcitonin was determined from the area under the plasma calcium level-time curve. The calcium level was determined using a colorimetric method.

Results. When the nasal formulation contained calcitonin plus saline or 0.125% octylmaltoside, little or no calcitonin was absorbed. However, plasma calcitonin levels were increased and plasma calcium levels were decreased when the nasal formulation contained calcitonin plus 0.125% or 0.25% tetradecylmaltoside. Maximal calcitonin levels were observed 7.5-10 min after nasal administration of the formulation. Ocular administration of calcitonin formulated with tetradecylmaltoside also resulted in calcitonin absorption, but less calcitonin absorption was found after ocular administration than after nasal administration.

Conclusion. The experimental data indicate that tetradecylmaltoside, but not octylmaltoside, can be effectively used to enhance the bioavailability of nasally and ocularly administered calcitonin.

calcitonin insulin blood glucose alkylglycoside pharmacokinetics 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Y. W. Chien. Novel drug delivery systems. 5th Ed. Marcel Dekker, New York, 1993.Google Scholar
  2. 2.
    R. Marcus. Treatment of osteoporosis. In S. Carruthers, B. Hoffman, K. L Melmon, D. Nierenberg (eds) Melmon and Morrelli's Clinical Pharmacology, 4th ed. McGraw-Hill, New York, 2000, pp. 703-711.Google Scholar
  3. 3.
    O. Torring, E. Bucht, U. Sjostedt, and H. E. Sjoberg. Salmon calcitonin treatment by nasal spray in primary hyperparathyroidism. Bone 12: 311-316 (1991).Google Scholar
  4. 4.
    Miacalcin® Nasal Spray. Novartis Pharmaceutical Corp. East Hanover, New Jersey, (1998).Google Scholar
  5. 5.
    N. G. M. Schipper, J. G. Romeijn, R. J. Verhoef, and F. W. H. M. Merkus. Hypocalcemic effect of salmon calcitonin following single and repeated nasal and intravenous administration in young rabbits. Calcif. Tissue Int. 54:50-55 (1994).Google Scholar
  6. 6.
    N. G. M. Schipper, J. C. Verhoef, S. G. Romeijn, and F. W. H. M. Merkus Methylated-ß-cyclodextrins are able to improve the nasal absorption of salmon calcitonin. Calcif. Tissue Int. 56:280-282 (1995).Google Scholar
  7. 7.
    S. Kagatani, T. Shinoda, M. Fukui, T. Ohmura, S. Hasumi, and T. Sonobe. Enhancement of nasal salmon calcitonin absorption by lauroylcarnitine chloride in rats. Pharm. Res. 13:739-743 (1996).Google Scholar
  8. 8.
    G. Yetkin, N. Celebi, I. Agabeyoglu, and N. Gokcora. The effect of dimethyl-ß-cyclodextrin and sodium taurocholate on the nasal bioavailability of salmon calcitonin in rabbits. STP Pharma Sci. 3:249-252 (1999).Google Scholar
  9. 9.
    K. Morimoto, K. Morisaka, and A. Kamada. Enhancement of nasal absorption of insulin and calcitonin using polyacrylic acid gel. J. Pharm. Pharmacol. 37:134-136 (1985).Google Scholar
  10. 10.
    D. J. Pillion, J. A. Atchison, R. X. Wang, and E. Meezan. Alkyglycosides enhance systemic absorption of insulin applied topically to the rat eye. J. Pharmacol. Exp. Ther. 271:1274-1280 (1994).Google Scholar
  11. 11.
    D. J. Pillion, J. A. Atchison, C. Gargiulo, R. X. Wang, P. Wang, and E. Meezan. Insulin delivery in nosedrops: New formulations containing alkylglycosides. Endocrinology 135:2386-2391 (1994).Google Scholar
  12. 12.
    D. J. Pillion, P. Wang, J. Yorks, P. McCann, and E. Meezan. Systemic absorption of insulin and glucagon applied topically to the eyes of rats and a diabetic dog. J. Ocul. Pharmacol. Ther. 11:283-295 (1995).Google Scholar
  13. 13.
    G. C. Y. Chiou and C. Y. Chuang. Improvement of systemic absorption of insulin through eyes with absorption enhancers. J. Pharm. Sci. 78:815-818 (1989).Google Scholar
  14. 14.
    D. J. Pillion, J. D. Bartlett, E. Meezan, M. Yang, R. J. Crain, and W. E. Grizzle. Systemic absorption of insulin delivered topically to the rat eye. Invest. Ophthalmol. Vis. Sci. 32:3021-3027 (1991).Google Scholar
  15. 15.
    T. Uchiyama, T. Sugiyama, Y. S. Quan, A. Kotani, N. Okada, T. Fujita, S. Muranishi, and A. Yamamoto. Enhanced permeability of insulin across the rat intestinal membrane by various absorption enhancers: Their intestinal mucosal toxicity and absorption-enhancing mechanism of lauryl-ß-D-maltopyranoside. J. Pharm. Pharmacol. 51:1241-1250 (1999).Google Scholar
  16. 16.
    D. J. Pillion, S. Hosmer, and E. Meezan. Dodecylmaltoside-mediated nasal and ocular absorption of Lyspro-insulin: Independence of surfactant action from multimer dissociation. Pharm. Res. 15:1641-1643 (1998).Google Scholar
  17. 17.
    W. J. Xia and H. Onyuksel. Mechanistic studies on surfactant-induced membrane permeability enhancement. Pharm. Res. 17:312-912 (2000).Google Scholar

Copyright information

© Plenum Publishing Corporation 2001

Authors and Affiliations

  • Fakhrul Ahsan
    • 1
  • John Arnold
    • 1
  • Elias Meezan
    • 1
  • Dennis J. Pillion
    • 1
  1. 1.Department of Pharmacology and Toxicology, School of MedicineUniversity of Alabama at BirminghamBirmingham

Personalised recommendations